Compound Screening TRIZ Cases

Engineered yeast and mammalian cell models express amyloid beta to screen for compounds that mitigate toxicity in neurodegenerative disease research.

Microcapillary arrays isolate viable protein samples after optical detection, resolving the trade-off between throughput and sample integrity.

Genetically engineered recombinant molecules target drug-resistant bacteria through ion channel formation, shortening the antibiotic development cycle.

Modulating annexin core domain interactions with C-type lectin receptors and LRP-1 to identify therapeutic compounds.

A ligand-guided selection method displaces aptamers using a specific antibody to isolate high-affinity binders.

Replacing costly mammalian models, this method uses C. elegans to assess synergistic effects of tenuazonic acid and patulin on growth and reproduction.

A formulation using bisabolol and glycerol ether ratios mitigates irritation from niacinamide and N-undecylenoyl-L-phenylalanine combinations.

Engineered chimeric Gαs subunits enable high-throughput ligand screening across diverse G protein-coupled receptors.

Genetically encoded calcium indicators replace invasive synthetic dyes to enable precise, repeated in vivo measurements of neural activity.

Formula compounds detect hydrogen peroxide through bioluminescence, bypassing horseradish peroxidase instability at high pH.

A protease biosensor uses specific cleavage sites to detect SARS-CoV-2 activity.

A transgenic mouse model with Prss56-driven Nf1 inactivation develops cutaneous and plexiform neurofibromas.

Antagonists suppress bitter taste receptor activity to improve food palatability and pharmaceutical compliance.

RNA interference sequences targeting C43 mRNA inhibit cell migration, while demethylation inhibitors increase promoter methylation to reduce metastasis.

Stable cell lines expressing functional voltage-gated sodium channels enable reliable membrane potential assays.

Extracted Fc domains eliminate IgA allergens and lot-to-lot impurities from traditional IVIG while preserving therapeutic efficacy.

BLT2 inhibitors suppress leukotriene B4 receptor signaling to reduce airway inflammation.

Monitoring CD3+CD4+CD57+ILT2+ T cells enables early detection of chronic lung allograft dysfunction before irreversible fibro-proliferative lesions develop.

A binary complex links a test compound to a presenter protein to modulate target biological activity.

Chaperones inhibit Z-AT polymerization in the endoplasmic reticulum, resolving liver toxicity while restoring lung function.

Identifying the HGFR IPT-3/IPT-4 interface resolves unclear binding mechanisms, enabling specific antagonists that reduce unwanted side effects.

A multi-marker stool assay detects SERPINF2 protein concentrations via targeted mass spectrometry for early diagnosis.

Monoclonal antibodies target phosphorylated ATR at position 1989, resolving low sensitivity in existing detection methods.

Blood RNA-Seq gene signatures classify sepsis mechanistic endotypes, resolving diagnostic heterogeneity and reducing unnecessary antibiotic use.